The research comes at a moment of rapid cultural and legal change. As psilocybin decriminalization gains momentum across the United States, many mental health professionals have expressed concern that individuals struggling with depression might forgo supervised care in favor of self-medicating with the substance, which remains federally illegal even as a handful of cities and states relax enforcement. Until now, however, no nationally representative study had tested whether that feared substitution was actually occurring among people with depression, leaving the debate largely driven by anecdote and speculation rather than data.

To fill that gap, the research team turned to the 2024 National Survey on Drug Use and Health, a large federal survey that tracks substance use and mental health across the United States. The 2024 iteration was the first to specifically record how recently respondents had used psilocybin, in addition to whether they had ever used it at all. That distinction matters, the researchers note, because lifetime prevalence says little about a person’s current life. Knowing that someone used psilocybin within the past year makes it possible to examine how that use relates to their present engagement with the mental health care system.

From the survey, the team analyzed data from 6,793 individuals aged 12 and older who had experienced a major depressive episode in the past year. Within this group, an estimated 7.3 percent reported using psilocybin during the same period. The researchers then compared treatment utilization between users and nonusers, examining whether psilocybin use was associated with reduced use of outpatient services, inpatient care, telehealth treatment or prescription medications for depression. The answer, across every category, was no: psilocybin use was not linked to lower utilization of any of these conventional forms of care.

What did differ was how users perceived their own needs. Among psilocybin users with a recent major depressive episode, 52.0 percent reported a perceived unmet need for mental health treatment, compared with 33.9 percent of nonusers, a difference the investigators describe as significant. The study also sketched a demographic profile of users, who were more likely to be younger, male, never married and employed full-time than their nonusing counterparts. Taken together, the findings suggest that psilocybin use and conventional care are co-occurring rather than competing, and that users may be turning to the substance because something in their existing care feels insufficient.

“Our main takeaway is that among people with depression, those using psilocybin aren’t abandoning conventional mental health care, which is good news,” said Avery Eun, first author of the study and a second-year medical student at UC San Diego School of Medicine. “But what is interesting is that even though they use mental health care at the same rate as nonusers, they still feel that their needs aren’t being met, which gives us an opportunity to better understand those unmet needs so we can help these patients.”

The researchers are careful to distinguish the kind of use captured by the survey from the psilocybin-assisted therapy being tested in clinical trials. Randomized controlled trials have shown that psilocybin can be effective for depression in highly monitored settings, where dosing is structured, psychological support is built into the protocol, and participants are screened and followed closely. Naturalistic use, by contrast, happens without any of these safeguards. People who obtain psilocybin on their own typically get it from inconsistent, unregulated sources and take it without clinical monitoring, meaning the safety and efficacy demonstrated in trials may not generalize to self-directed use outside the clinic.

Why might psilocybin users feel their needs are going unmet at such high rates? The study raises but does not answer that question. One hypothesis advanced by the researchers is that the gap between perceived need and actual treatment receipt may drive some individuals toward self-directed symptom management with psychedelics. In other words, rather than psilocybin use causing disengagement from care, unmet needs within the care system might be pushing people toward psilocybin in the first place, either as an alternative or as an adjunct to the treatment they are already receiving. The authors emphasize, however, that proving this directional hypothesis would require further research, and the current study establishes an association rather than a causal pathway.

The findings also carry implications for policy. The researchers note that decriminalization and similar policy changes may improve patient safety by reducing stigma and creating a safer environment for individuals to share their psilocybin experiences with their providers. If patients fear legal or professional consequences for disclosing psychedelic use, clinicians lose the chance to understand what those patients are seeking and why. Openness, the authors suggest, could turn a hidden behavior into a clinical conversation, allowing providers to assess risk, offer guidance and identify the unmet needs that may underlie the use in the first place.

“It’s really important for providers to interpret psilocybin use in their patients differently,” said Eun. “Rather than assuming a patient is retreating from care, providers can use this as a way to start a conversation about the motivations for use. If psilocybin is being used for therapeutic reasons, it may be an opportunity to discuss whether the patient feels their needs are being met by conventional care and what can be done to help if not.” The study was conducted by Eun together with co-authors Kevin H. Yang, MD, of the University of California, Los Angeles, and Joseph J. Palamar, PhD, of New York University, and was supported by the National Institute on Drug Abuse of the National Institutes of Health. For a field grappling with how psychedelics fit into mainstream psychiatry, the message of this first national snapshot is clear: patients are not choosing between psilocybin and care, they are pursuing both, and the most productive clinical response may be to ask why.

Subject of Research: Psilocybin use and mental health treatment utilization among individuals with depression in the United States

Article Title: Contrary to fears, psilocybin users with depression continue to seek treatment

Article References: Contrary to fears, psilocybin users with depression continue to seek treatment. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: psilocybin, depression, mental health care, psychedelics, National Survey on Drug Use and Health, UC San Diego, Psychological Medicine, unmet treatment need, decriminalization, self-medication, psilocybin-assisted therapy, treatment utilization